carteolol has been researched along with labetalol in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Baba, T; Takebe, K; Tomiyama, T | 1 |
Baba, T; Murabayashi, S; Takebe, K; Tomiyama, T | 1 |
Carlo, MJ; Patrick, AL | 1 |
2 trial(s) available for carteolol and labetalol
Article | Year |
---|---|
Metabolic effects of carteolol and dilevalol in essential hypertension.
Topics: Carteolol; Humans; Hypertension; Labetalol | 1992 |
Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aldosterone; Blood Proteins; Carteolol; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Kidney; Kidney Function Tests; Labetalol; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic; Renal Circulation; Renin | 1990 |
6 other study(ies) available for carteolol and labetalol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Further exploration of the collision-induced dissociation of select beta blockers: Acebutolol, atenolol, bisoprolol, carteolol, and labetalol.
Topics: Acebutolol; Atenolol; Bisoprolol; Carteolol; Chromatography, Liquid; Labetalol; Tandem Mass Spectrometry | 2023 |